BusinessTelix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public OfferingBy Nasdaq OMXNov 8, 2017, 11:20 PM UTC
BusinessTelix Pharmaceuticals and ANMI Partner for Prostate Cancer ImagingBy Nasdaq OMXOct 23, 2017, 11:00 PM UTC
BusinessTelix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)By Nasdaq OMXOct 23, 2017, 9:00 PM UTC
BusinessUniversity of Melbourne and Telix Pharmaceuticals Establish Cancer Translational Research PartnershipBy Nasdaq OMXOct 17, 2017, 9:19 PM UTC
BusinessTelix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET TechnologyBy Nasdaq OMXSep 20, 2017, 1:46 AM UTC
BusinessKevin McCann and Mark Nelson Appointed to the Board of Directors of Telix Pharmaceuticals LimitedBy Nasdaq OMXSep 17, 2017, 10:00 PM UTC
